Literature DB >> 9930332

Polyethylenimine-based intravenous delivery of transgenes to mouse lung.

D Goula1, C Benoist, S Mantero, G Merlo, G Levi, B A Demeneix.   

Abstract

Generally, cationic vector-based intravenous delivery of DNA is hindered by interactions of positively charged complexes with serum proteins. However, if optimally formulated, cationic vectors can provide reasonable levels of transfection in the lung either by intravenous or intrapulmonary routes. We investigated the in vivo transfection capacity of a cationic polymer: linear, 22 kDa polyethylenimine. PEI/DNA complexes were formulated in 5% glucose and delivered into adult mice through the tail vein. Two marker genes were used, beta-galactosidase and luciferase. High levels of luciferase expression (10(7) RLU/mg protein) were found in the lung when DNA was complexed with PEI at a ratio of 4 nitrogen equivalents per DNA phosphate. Lower levels of transfection were found in the heart, spleen, liver and kidney. Expression was dose- and time-dependent in all tissues examined. In the lung, beta-galactosidase staining showed transgene expression in clusters of 10 or more pulmonary cells including the alveolar endothelium, squamous and great alveolar epithelial cells (type I and II pneumocytes) and septal cells. These findings indicate that the complexes pass the capillary barrier in the lung. Although the delivery mechanism requires elucidation, linear PEI has promise as a vector for intravenous transfer of therapeutic genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930332     DOI: 10.1038/sj.gt.3300717

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  54 in total

1.  Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity.

Authors:  Olivia M Merkel; Meredith A Mintzer; Damiano Librizzi; Olga Samsonova; Tanja Dicke; Brian Sproat; Holger Garn; Peter J Barth; Eric E Simanek; Thomas Kissel
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  In vivo SiRNA transfection and gene knockdown in spinal cord via rapid noninvasive lumbar intrathecal injections in mice.

Authors:  Christian Njoo; Celine Heinl; Rohini Kuner
Journal:  J Vis Exp       Date:  2014-03-22       Impact factor: 1.355

Review 3.  Nonviral gene delivery: what we know and what is next.

Authors:  Xiang Gao; Keun-Sik Kim; Dexi Liu
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

Review 4.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

Review 5.  Subcellular targeting strategies for drug design and delivery.

Authors:  Lawrence Rajendran; Hans-Joachim Knölker; Kai Simons
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 6.  Nonviral gene delivery: principle, limitations, and recent progress.

Authors:  Mohammed S Al-Dosari; Xiang Gao
Journal:  AAPS J       Date:  2009-10-16       Impact factor: 4.009

7.  Fluorescence dynamics of DNA condensed by the molecular crowding agent poly(ethylene glycol).

Authors:  Mamata H Kombrabail; G Krishnamoorthy
Journal:  J Fluoresc       Date:  2005-09       Impact factor: 2.217

8.  A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.

Authors:  Sarah Parker Read; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

9.  New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery.

Authors:  Jian-Ming Lü; Zhengdong Liang; Xiaoxiao Wang; Jianhua Gu; Qizhi Yao; Changyi Chen
Journal:  Nanomedicine (Lond)       Date:  2016-07-26       Impact factor: 5.307

10.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.